NORTH AMERICA RETINAL IMAGING DEVICES MARKET FORECAST 2023-2032

The North America retinal imaging devices market growth evaluation includes the analysis of the United States and Canada. The aging demographic profile of the United States has contributed to a notable increase in the prevalence of age-related eye conditions, such as macular degeneration and diabetic retinopathy. Consequently, there is a heightened demand for advanced retinal imaging technologies capable of aiding in the early detection, precise diagnosis, and effective management of these ocular disorders.

Furthermore, the escalating incidence of diabetes within the United States has further intensified the need for state-of-the-art retinal imaging solutions. Diabetic retinopathy, a prominent complication of diabetes, mandates regular retinal examinations to enable timely interventions and mitigate the risk of vision impairment. A study featured in JAMA Ophthalmology in 2021 estimated that approximately 9.60 million individuals in the US were afflicted with diabetic retinopathy, with an additional 1.84 million experiencing vision-threatening diabetic retinopathy.

Aligning with these healthcare trends, the adoption of telemedicine and remote healthcare solutions has witnessed a notable surge across the nation. Retinal imaging technology plays a pivotal role in facilitating remote assessments of patients’ ocular health, thereby enabling virtual consultations. This innovative approach empowers healthcare providers to reach individuals in geographically remote or underserved areas, enhancing access to crucial eye care services.

The North America retinal imaging devices market segmentation includes end use and device type. The device type segment includes fundus camera, optical coherence tomography, and fluorescein angiography.

Fluorescein angiography (FA) is a specialized imaging modality employed in retinal diagnostics for visualizing the vasculature and circulatory patterns within the retina and choroid. This procedure entails the intravenous administration of fluorescein, a fluorescent dye, followed by the capture of a sequential image series that tracks the movement of the dye as it traverses the retinal and choroidal vascular systems. Fluorescein angiography furnishes valuable insights into the dynamic vascular processes and pathologies of the retina, serving as a valuable tool for the diagnosis, ongoing assessment, and treatment management of a diverse range of retinal conditions.

The administration of fluorescein dye occurs via intravenous injection into the patient’s arm, typically utilizing a vein. This dye rapidly disperses throughout the circulatory system, swiftly reaching the retinal and choroidal arteries in a matter of seconds. A sequence of images is then obtained using a fundus camera equipped with appropriate filters, capturing the journey of the fluorescein dye through the retinal and choroidal veins. These images provide a comprehensive depiction of the dye’s path, highlighting any areas exhibiting abnormal vascular leakage, obstructions, or deviations in blood flow.

Some of the leading players in the North America retinal imaging devices market are Optos plc, Escalon Medical Corp, Forus Health Pvt Ltd, Heidelberg Engineering GmbH, etc.

Escalon Medical Corp specializes in the distribution and development of high-quality optometric and ophthalmic products. The company’s product line includes different optometric and ophthalmic devices like surgical instruments, diagnostic tools, and ultrasound systems. These accessories address a vast range of needs in eye care, from detecting ocular disorders to executing precise procedures. It is headquartered in Wayne, Pennsylvania, the United States. 

One of its key products, the B-Scan Plus Ophthalmic Ultrasound System, generates cross-sectional images of the eye’s anatomy and helps visualize vitreous opacities and retinal detachments.